At an EGM of Sulzer Ltd’s shareholders, to be held in Winterthur on September 20, 2021, Sulzer Ltd’s board of directors will propose to the shareholders to approve the demerger plan published at the end of May 2021 and to formally incorporate medmix AG after expiry of the two-month creditor notification period and the two-month shareholder review period without any requests from shareholders or claims by creditors. The Sulzer Ltd board of directors also confirmed the nominations for the chairman and members of medmix AG’s board of directors as well as for the members of the remuneration committee of medmix AG. With Grégoire Poux-Guillaume, Jill Lee and Marco Musetti, three non-executive and independent candidates are proposed to be elected to the medmix AG board of directors by the shareholders at the EGM. At the EGM, shareholders will among other matters also be requested to vote on the maximum aggregate compensation of the medmix AG board of directors until the 2022 annual general meeting of shareholders and the maximum aggregate compensation of the medmix AG executive committee for the remainder of 2021 and for 2022 as well as on the election of the auditors and the independent proxy for medmix AG.

The Sulzer Ltd board of directors has also approved medmix AG’s audited combined and carve-out financial statements for 2018-2020 and its unaudited interim combined and carve-out financial statements for the first six months of 2021. These documents are available on Sulzer Ltd’s website (www.sulzer.com/aps-spinoff), together with the other documents relating to the demerger.

The EGM invitation is expected to be dispatched to Sulzer Ltd shareholders on August 20, 2021 and will be available at www.sulzer.com/egm.